#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=The main finding of our study is that the risk of AKI rose proportionally according to the amount of pRBC and FFP transfusions in both ABO-c and ABO-i LT , but this association of pRBC and FFP transfusions with post-transplant AKI was stronger in ABO-i LT than in ABO-c LT .
2-1	14-17	The	abstract[2]	new[2]	_	_
2-2	18-22	main	abstract[2]	new[2]	_	_
2-3	23-30	finding	abstract[2]	new[2]	_	_
2-4	31-33	of	abstract[2]	new[2]	_	_
2-5	34-37	our	abstract[2]|person|abstract[4]	new[2]|acc|new[4]	ana|coref	4-4|17-22[161_4]
2-6	38-43	study	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-7	44-46	is	_	_	_	_
2-8	47-51	that	_	_	_	_
2-9	52-55	the	abstract[5]	new[5]	coref	7-18[0_5]
2-10	56-60	risk	abstract[5]	new[5]	_	_
2-11	61-63	of	abstract[5]	new[5]	_	_
2-12	64-67	AKI	abstract[5]|abstract	new[5]|new	coref	2-40[18_0]
2-13	68-72	rose	_	_	_	_
2-14	73-87	proportionally	_	_	_	_
2-15	88-97	according	_	_	_	_
2-16	98-100	to	_	_	_	_
2-17	101-104	the	abstract[7]	new[7]	_	_
2-18	105-111	amount	abstract[7]	new[7]	_	_
2-19	112-114	of	abstract[7]	new[7]	_	_
2-20	115-119	pRBC	abstract[7]|abstract|abstract[10]	new[7]|new|new[10]	coref|coref	2-35|2-35[17_10]
2-21	120-123	and	abstract[7]|abstract[10]	new[7]|new[10]	_	_
2-22	124-127	FFP	abstract[7]|substance|abstract[10]	new[7]|new|new[10]	coref	2-37
2-23	128-140	transfusions	abstract[7]|abstract[10]	new[7]|new[10]	_	_
2-24	141-143	in	_	_	_	_
2-25	144-148	both	abstract[11]	new[11]	coref	2-49[0_11]
2-26	149-154	ABO-c	abstract[11]	new[11]	_	_
2-27	155-158	and	_	_	_	_
2-28	159-164	ABO-i	abstract	new	coref	2-45
2-29	165-167	LT	abstract	new	coref	2-45[20_0]
2-30	168-169	,	_	_	_	_
2-31	170-173	but	_	_	_	_
2-32	174-178	this	abstract[14]	new[14]	_	_
2-33	179-190	association	abstract[14]	new[14]	_	_
2-34	191-193	of	abstract[14]	new[14]	_	_
2-35	194-198	pRBC	abstract[14]|abstract|abstract[17]	new[14]|giv|giv[17]	coref|coref	3-32[34_17]|15-5
2-36	199-202	and	abstract[14]|abstract[17]	new[14]|giv[17]	_	_
2-37	203-206	FFP	abstract[14]|substance|abstract[17]	new[14]|giv|giv[17]	coref	11-13
2-38	207-219	transfusions	abstract[14]|abstract[17]	new[14]|giv[17]	_	_
2-39	220-224	with	abstract[14]|abstract[17]	new[14]|giv[17]	_	_
2-40	225-240	post-transplant	abstract[14]|abstract[17]|abstract[18]	new[14]|giv[17]|giv[18]	coref	3-4[0_18]
2-41	241-244	AKI	abstract[14]|abstract[17]|abstract[18]	new[14]|giv[17]|giv[18]	_	_
2-42	245-248	was	_	_	_	_
2-43	249-257	stronger	_	_	_	_
2-44	258-260	in	_	_	_	_
2-45	261-266	ABO-i	abstract|abstract[20]	giv|giv[20]	coref|coref	2-49[22_20]|3-24
2-46	267-269	LT	abstract[20]	giv[20]	_	_
2-47	270-274	than	_	_	_	_
2-48	275-277	in	_	_	_	_
2-49	278-283	ABO-c	abstract|abstract[22]	giv|giv[22]	coref|coref	3-24[31_22]|5-16
2-50	284-286	LT	abstract[22]	giv[22]	_	_
2-51	287-288	.	_	_	_	_

#Text=Given that the AKI rates increased in patients with preoperative anemia and that the influence of transfusion on AKI was more pronounced in ABO-i LT patients , any efforts to reduce perioperative transfusions may protect patients with ABO-i LT against AKI .
3-1	289-294	Given	_	_	_	_
3-2	295-299	that	_	_	_	_
3-3	300-303	the	abstract[24]	new[24]	_	_
3-4	304-307	AKI	abstract|abstract[24]	giv|new[24]	coref	3-19
3-5	308-313	rates	abstract[24]	new[24]	_	_
3-6	314-323	increased	_	_	_	_
3-7	324-326	in	_	_	_	_
3-8	327-335	patients	person[25]	new[25]	coref	3-24[32_25]
3-9	336-340	with	person[25]	new[25]	_	_
3-10	341-353	preoperative	person[25]|abstract[26]	new[25]|new[26]	_	_
3-11	354-360	anemia	person[25]|abstract[26]	new[25]|new[26]	_	_
3-12	361-364	and	_	_	_	_
3-13	365-369	that	_	_	_	_
3-14	370-373	the	abstract[27]	new[27]	_	_
3-15	374-383	influence	abstract[27]	new[27]	_	_
3-16	384-386	of	abstract[27]	new[27]	_	_
3-17	387-398	transfusion	abstract[27]|abstract	new[27]|new	coref	10-32[98_0]
3-18	399-401	on	abstract[27]	new[27]	_	_
3-19	402-405	AKI	abstract[27]|abstract	new[27]|giv	coref	3-41
3-20	406-409	was	_	_	_	_
3-21	410-414	more	_	_	_	_
3-22	415-425	pronounced	_	_	_	_
3-23	426-428	in	_	_	_	_
3-24	429-434	ABO-i	abstract|abstract[31]|person[32]	giv|giv[31]|giv[32]	coref|coref|coref	3-36[35_32]|3-38|3-38[37_31]
3-25	435-437	LT	abstract[31]|person[32]	giv[31]|giv[32]	_	_
3-26	438-446	patients	person[32]	giv[32]	_	_
3-27	447-448	,	_	_	_	_
3-28	449-452	any	event[33]	new[33]	_	_
3-29	453-460	efforts	event[33]	new[33]	_	_
3-30	461-463	to	event[33]	new[33]	_	_
3-31	464-470	reduce	event[33]	new[33]	_	_
3-32	471-484	perioperative	event[33]|abstract[34]	new[33]|giv[34]	coref	12-32[124_34]
3-33	485-497	transfusions	event[33]|abstract[34]	new[33]|giv[34]	_	_
3-34	498-501	may	_	_	_	_
3-35	502-509	protect	_	_	_	_
3-36	510-518	patients	person[35]	giv[35]	coref	11-3[102_35]
3-37	519-523	with	person[35]	giv[35]	_	_
3-38	524-529	ABO-i	person[35]|abstract|abstract[37]	giv[35]|giv|giv[37]	coref|coref	5-7|5-7[50_37]
3-39	530-532	LT	person[35]|abstract[37]	giv[35]|giv[37]	_	_
3-40	533-540	against	_	_	_	_
3-41	541-544	AKI	abstract	giv	coref	6-13
3-42	545-546	.	_	_	_	_

#Text=However , as our observations were from a retrospective analysis , prospective trials are required to confirm our hypothesis .
4-1	547-554	However	_	_	_	_
4-2	555-556	,	_	_	_	_
4-3	557-559	as	_	_	_	_
4-4	560-563	our	person|abstract[40]	giv|new[40]	ana	4-18
4-5	564-576	observations	abstract[40]	new[40]	_	_
4-6	577-581	were	_	_	_	_
4-7	582-586	from	_	_	_	_
4-8	587-588	a	abstract[41]	new[41]	coref	20-8[177_41]
4-9	589-602	retrospective	abstract[41]	new[41]	_	_
4-10	603-611	analysis	abstract[41]	new[41]	_	_
4-11	612-613	,	_	_	_	_
4-12	614-625	prospective	abstract[42]	new[42]	_	_
4-13	626-632	trials	abstract[42]	new[42]	_	_
4-14	633-636	are	_	_	_	_
4-15	637-645	required	_	_	_	_
4-16	646-648	to	_	_	_	_
4-17	649-656	confirm	_	_	_	_
4-18	657-660	our	person|abstract[44]	giv|new[44]	ana	17-22
4-19	661-671	hypothesis	abstract[44]	new[44]	_	_
4-20	672-673	.	_	_	_	_

#Text=Patient mortality and graft survival after ABO-i LT have been reported to be comparable to ABO-c LT , although there is still concern regarding the high incidence of antibody-mediated rejection , including biliary stricture related to a high isoagglutinin titer .
5-1	674-681	Patient	person|abstract[46]	new|new[46]	coref	7-7[68_46]
5-2	682-691	mortality	abstract[46]	new[46]	_	_
5-3	692-695	and	_	_	_	_
5-4	696-701	graft	abstract|event[48]	new|new[48]	coref	7-4
5-5	702-710	survival	event[48]	new[48]	_	_
5-6	711-716	after	event[48]	new[48]	_	_
5-7	717-722	ABO-i	event[48]|abstract|abstract[50]	new[48]|giv|giv[50]	coref|coref	5-16[52_50]|7-23
5-8	723-725	LT	event[48]|abstract[50]	new[48]|giv[50]	_	_
5-9	726-730	have	_	_	_	_
5-10	731-735	been	_	_	_	_
5-11	736-744	reported	_	_	_	_
5-12	745-747	to	_	_	_	_
5-13	748-750	be	_	_	_	_
5-14	751-761	comparable	_	_	_	_
5-15	762-764	to	_	_	_	_
5-16	765-770	ABO-c	abstract|abstract[52]	giv|giv[52]	coref	7-23[76_52]
5-17	771-773	LT	abstract[52]	giv[52]	_	_
5-18	774-775	,	_	_	_	_
5-19	776-784	although	_	_	_	_
5-20	785-790	there	_	_	_	_
5-21	791-793	is	_	_	_	_
5-22	794-799	still	_	_	_	_
5-23	800-807	concern	abstract[53]	new[53]	_	_
5-24	808-817	regarding	abstract[53]	new[53]	_	_
5-25	818-821	the	abstract[53]|abstract[54]	new[53]|new[54]	_	_
5-26	822-826	high	abstract[53]|abstract[54]	new[53]|new[54]	_	_
5-27	827-836	incidence	abstract[53]|abstract[54]	new[53]|new[54]	_	_
5-28	837-839	of	abstract[53]|abstract[54]	new[53]|new[54]	_	_
5-29	840-857	antibody-mediated	abstract[53]|abstract[54]|event[55]	new[53]|new[54]|new[55]	_	_
5-30	858-867	rejection	abstract[53]|abstract[54]|event[55]	new[53]|new[54]|new[55]	_	_
5-31	868-869	,	abstract[53]|abstract[54]|event[55]	new[53]|new[54]|new[55]	_	_
5-32	870-879	including	abstract[53]|abstract[54]|event[55]	new[53]|new[54]|new[55]	_	_
5-33	880-887	biliary	abstract[53]|abstract[54]|event[55]|abstract[56]	new[53]|new[54]|new[55]|new[56]	_	_
5-34	888-897	stricture	abstract[53]|abstract[54]|event[55]|abstract[56]	new[53]|new[54]|new[55]|new[56]	_	_
5-35	898-905	related	abstract[53]|abstract[54]|event[55]|abstract[56]	new[53]|new[54]|new[55]|new[56]	_	_
5-36	906-908	to	abstract[53]|abstract[54]|event[55]|abstract[56]	new[53]|new[54]|new[55]|new[56]	_	_
5-37	909-910	a	abstract[53]|abstract[54]|event[55]|abstract[56]|object[58]	new[53]|new[54]|new[55]|new[56]|new[58]	coref	6-1[60_58]
5-38	911-915	high	abstract[53]|abstract[54]|event[55]|abstract[56]|object[58]	new[53]|new[54]|new[55]|new[56]|new[58]	_	_
5-39	916-929	isoagglutinin	abstract[53]|abstract[54]|event[55]|abstract[56]|substance|object[58]	new[53]|new[54]|new[55]|new[56]|new|new[58]	coref	6-3
5-40	930-935	titer	abstract[53]|abstract[54]|event[55]|abstract[56]|object[58]	new[53]|new[54]|new[55]|new[56]|new[58]	_	_
5-41	936-937	.	_	_	_	_

#Text=This high isoagglutinin titer may provoke another major organ injury , including AKI , through an immunologic response .
6-1	938-942	This	object[60]	giv[60]	coref	8-16[82_60]
6-2	943-947	high	object[60]	giv[60]	_	_
6-3	948-961	isoagglutinin	substance|object[60]	giv|giv[60]	coref	8-18
6-4	962-967	titer	object[60]	giv[60]	_	_
6-5	968-971	may	_	_	_	_
6-6	972-979	provoke	_	_	_	_
6-7	980-987	another	event[62]	new[62]	coref	9-12[88_62]
6-8	988-993	major	event[62]	new[62]	_	_
6-9	994-999	organ	abstract|event[62]	new|new[62]	coref	9-9
6-10	1000-1006	injury	event[62]	new[62]	_	_
6-11	1007-1008	,	event[62]	new[62]	_	_
6-12	1009-1018	including	event[62]	new[62]	_	_
6-13	1019-1022	AKI	event[62]|abstract	new[62]|giv	coref	7-2
6-14	1023-1024	,	_	_	_	_
6-15	1025-1032	through	_	_	_	_
6-16	1033-1035	an	abstract[64]	new[64]	coref	15-11[140_64]
6-17	1036-1047	immunologic	abstract[64]	new[64]	_	_
6-18	1048-1056	response	abstract[64]	new[64]	_	_
6-19	1057-1058	.	_	_	_	_

#Text=As AKI affects graft outcomes and mortality after liver transplantation , it is important to elucidate modifiable risk factors of AKI in ABO-i LT .
7-1	1059-1061	As	_	_	_	_
7-2	1062-1065	AKI	abstract	giv	coref	7-21
7-3	1066-1073	affects	_	_	_	_
7-4	1074-1079	graft	abstract|abstract[67]	giv|new[67]	_	_
7-5	1080-1088	outcomes	abstract[67]	new[67]	_	_
7-6	1089-1092	and	_	_	_	_
7-7	1093-1102	mortality	abstract[68]	giv[68]	_	_
7-8	1103-1108	after	abstract[68]	giv[68]	_	_
7-9	1109-1114	liver	abstract[68]|object|event[70]	giv[68]|new|new[70]	ana|coref	7-12[0_70]|12-16
7-10	1115-1130	transplantation	abstract[68]|event[70]	giv[68]|new[70]	_	_
7-11	1131-1132	,	_	_	_	_
7-12	1133-1135	it	event	giv	coref	10-23
7-13	1136-1138	is	_	_	_	_
7-14	1139-1148	important	_	_	_	_
7-15	1149-1151	to	_	_	_	_
7-16	1152-1161	elucidate	_	_	_	_
7-17	1162-1172	modifiable	abstract[73]	new[73]	coref	20-5[176_73]
7-18	1173-1177	risk	abstract|abstract[73]	giv|new[73]	coref	12-8
7-19	1178-1185	factors	abstract[73]	new[73]	_	_
7-20	1186-1188	of	abstract[73]	new[73]	_	_
7-21	1189-1192	AKI	abstract[73]|abstract	new[73]|giv	coref	8-4
7-22	1193-1195	in	_	_	_	_
7-23	1196-1201	ABO-i	abstract|abstract[76]	giv|giv[76]	coref|coref	8-9|8-9[80_76]
7-24	1202-1204	LT	abstract[76]	giv[76]	_	_
7-25	1205-1206	.	_	_	_	_

#Text=The reason why AKI occurs more frequently in ABO-i LT is not certain , although the high isoagglutinin titer may play a role .
8-1	1207-1210	The	abstract[77]	new[77]	_	_
8-2	1211-1217	reason	abstract[77]	new[77]	_	_
8-3	1218-1221	why	abstract[77]	new[77]	_	_
8-4	1222-1225	AKI	abstract[77]|abstract	new[77]|giv	coref	12-11
8-5	1226-1232	occurs	abstract[77]	new[77]	_	_
8-6	1233-1237	more	abstract[77]	new[77]	_	_
8-7	1238-1248	frequently	abstract[77]	new[77]	_	_
8-8	1249-1251	in	abstract[77]	new[77]	_	_
8-9	1252-1257	ABO-i	abstract[77]|abstract|abstract[80]	new[77]|giv|giv[80]	coref|coref	11-5|11-5[104_80]
8-10	1258-1260	LT	abstract[77]|abstract[80]	new[77]|giv[80]	_	_
8-11	1261-1263	is	_	_	_	_
8-12	1264-1267	not	_	_	_	_
8-13	1268-1275	certain	_	_	_	_
8-14	1276-1277	,	_	_	_	_
8-15	1278-1286	although	_	_	_	_
8-16	1287-1290	the	object[82]	giv[82]	coref	9-1[85_82]
8-17	1291-1295	high	object[82]	giv[82]	_	_
8-18	1296-1309	isoagglutinin	substance|object[82]	giv|giv[82]	coref	9-3
8-19	1310-1315	titer	object[82]	giv[82]	_	_
8-20	1316-1319	may	_	_	_	_
8-21	1320-1324	play	_	_	_	_
8-22	1325-1326	a	abstract[83]	new[83]	_	_
8-23	1327-1331	role	abstract[83]	new[83]	_	_
8-24	1332-1333	.	_	_	_	_

#Text=A high isoagglutinin titer may lead to major organ damage through possible immunologic injury .
9-1	1334-1335	A	object[85]	giv[85]	coref	19-15[174_85]
9-2	1336-1340	high	object[85]	giv[85]	_	_
9-3	1341-1354	isoagglutinin	substance|object[85]	giv|giv[85]	coref	19-17
9-4	1355-1360	titer	object[85]	giv[85]	_	_
9-5	1361-1364	may	_	_	_	_
9-6	1365-1369	lead	_	_	_	_
9-7	1370-1372	to	_	_	_	_
9-8	1373-1378	major	event[87]	new[87]	_	_
9-9	1379-1384	organ	abstract|event[87]	giv|new[87]	_	_
9-10	1385-1391	damage	event[87]	new[87]	_	_
9-11	1392-1399	through	_	_	_	_
9-12	1400-1408	possible	event[88]	giv[88]	_	_
9-13	1409-1420	immunologic	event[88]	giv[88]	_	_
9-14	1421-1427	injury	event[88]	giv[88]	_	_
9-15	1428-1429	.	_	_	_	_

#Text=In addition , the prevalent baseline metabolic alkalosis , low platelet count , and high incidence of mild arterial hypoxemia prior to transplantation surgery may contribute to the high incidence of intraoperative transfusion and low oxygen delivery to the kidney .
10-1	1430-1432	In	_	_	_	_
10-2	1433-1441	addition	_	_	_	_
10-3	1442-1443	,	_	_	_	_
10-4	1444-1447	the	substance[90]	new[90]	_	_
10-5	1448-1457	prevalent	substance[90]	new[90]	_	_
10-6	1458-1466	baseline	abstract|substance[90]	new|new[90]	coref	25-10
10-7	1467-1476	metabolic	substance[90]	new[90]	_	_
10-8	1477-1486	alkalosis	substance[90]	new[90]	_	_
10-9	1487-1488	,	_	_	_	_
10-10	1489-1492	low	abstract[92]	new[92]	_	_
10-11	1493-1501	platelet	substance|abstract[92]	new|new[92]	_	_
10-12	1502-1507	count	abstract[92]	new[92]	_	_
10-13	1508-1509	,	_	_	_	_
10-14	1510-1513	and	_	_	_	_
10-15	1514-1518	high	abstract[93]	new[93]	_	_
10-16	1519-1528	incidence	abstract[93]	new[93]	_	_
10-17	1529-1531	of	abstract[93]	new[93]	_	_
10-18	1532-1536	mild	abstract[93]|abstract[94]	new[93]|new[94]	_	_
10-19	1537-1545	arterial	abstract[93]|abstract[94]	new[93]|new[94]	_	_
10-20	1546-1555	hypoxemia	abstract[93]|abstract[94]	new[93]|new[94]	_	_
10-21	1556-1561	prior	abstract[93]	new[93]	_	_
10-22	1562-1564	to	abstract[93]	new[93]	_	_
10-23	1565-1580	transplantation	abstract[93]|event|event[96]	new[93]|giv|new[96]	coref|coref	11-20[0_96]|12-16[117_0]
10-24	1581-1588	surgery	abstract[93]|event[96]	new[93]|new[96]	_	_
10-25	1589-1592	may	_	_	_	_
10-26	1593-1603	contribute	_	_	_	_
10-27	1604-1606	to	_	_	_	_
10-28	1607-1610	the	event[97]	new[97]	_	_
10-29	1611-1615	high	event[97]	new[97]	_	_
10-30	1616-1625	incidence	event[97]	new[97]	_	_
10-31	1626-1628	of	event[97]	new[97]	_	_
10-32	1629-1643	intraoperative	event[97]|abstract[98]	new[97]|giv[98]	coref	11-13[107_98]
10-33	1644-1655	transfusion	event[97]|abstract[98]	new[97]|giv[98]	_	_
10-34	1656-1659	and	event[97]	new[97]	_	_
10-35	1660-1663	low	event[97]|event[100]	new[97]|new[100]	coref	16-21[150_100]
10-36	1664-1670	oxygen	event[97]|substance|event[100]	new[97]|new|new[100]	coref	16-22
10-37	1671-1679	delivery	event[97]|event[100]	new[97]|new[100]	_	_
10-38	1680-1682	to	event[97]|event[100]	new[97]|new[100]	_	_
10-39	1683-1686	the	event[97]|event[100]|object[101]	new[97]|new[100]|new[101]	_	_
10-40	1687-1693	kidney	event[97]|event[100]|object[101]	new[97]|new[100]|new[101]	_	_
10-41	1694-1695	.	_	_	_	_

#Text=Furthermore , patients with ABO-i LT already receive a substantial amount of FFP transfusion for plasma exchange prior to surgery .
11-1	1696-1707	Furthermore	_	_	_	_
11-2	1708-1709	,	_	_	_	_
11-3	1710-1718	patients	person[102]	giv[102]	coref	12-27[120_102]
11-4	1719-1723	with	person[102]	giv[102]	_	_
11-5	1724-1729	ABO-i	person[102]|abstract|abstract[104]	giv[102]|giv|giv[104]	coref|coref	12-29|12-29[122_104]
11-6	1730-1732	LT	person[102]|abstract[104]	giv[102]|giv[104]	_	_
11-7	1733-1740	already	_	_	_	_
11-8	1741-1748	receive	_	_	_	_
11-9	1749-1750	a	abstract[105]	new[105]	_	_
11-10	1751-1762	substantial	abstract[105]	new[105]	_	_
11-11	1763-1769	amount	abstract[105]	new[105]	_	_
11-12	1770-1772	of	abstract[105]	new[105]	_	_
11-13	1773-1776	FFP	abstract[105]|substance|abstract[107]	new[105]|giv|giv[107]	coref|coref	12-1|13-13[127_107]
11-14	1777-1788	transfusion	abstract[105]|abstract[107]	new[105]|giv[107]	_	_
11-15	1789-1792	for	abstract[105]|abstract[107]	new[105]|giv[107]	_	_
11-16	1793-1799	plasma	abstract[105]|abstract[107]|substance|event[109]	new[105]|giv[107]|new|new[109]	coref|coref	22-6|22-5[190_109]
11-17	1800-1808	exchange	abstract[105]|abstract[107]|event[109]	new[105]|giv[107]|new[109]	_	_
11-18	1809-1814	prior	_	_	_	_
11-19	1815-1817	to	_	_	_	_
11-20	1818-1825	surgery	event	giv	coref	12-13[115_0]
11-21	1826-1827	.	_	_	_	_

#Text=FFP has been reported to be a risk factor for AKI after surgery , including liver transplantation , and the risk of AKI may increase when patients with ABO-i LT receive intraoperative FFP transfusions .
12-1	1828-1831	FFP	substance	giv	coref	12-33
12-2	1832-1835	has	_	_	_	_
12-3	1836-1840	been	_	_	_	_
12-4	1841-1849	reported	_	_	_	_
12-5	1850-1852	to	_	_	_	_
12-6	1853-1855	be	_	_	_	_
12-7	1856-1857	a	abstract[113]	new[113]	_	_
12-8	1858-1862	risk	abstract|abstract[113]	giv|new[113]	coref	12-20[118_0]
12-9	1863-1869	factor	abstract[113]	new[113]	_	_
12-10	1870-1873	for	abstract[113]	new[113]	_	_
12-11	1874-1877	AKI	abstract[113]|abstract	new[113]|giv	coref	12-23
12-12	1878-1883	after	abstract[113]	new[113]	_	_
12-13	1884-1891	surgery	abstract[113]|event[115]	new[113]|giv[115]	coref	15-24[0_115]
12-14	1892-1893	,	abstract[113]|event[115]	new[113]|giv[115]	_	_
12-15	1894-1903	including	abstract[113]|event[115]	new[113]|giv[115]	_	_
12-16	1904-1909	liver	abstract[113]|event[115]|object|event[117]	new[113]|giv[115]|giv|giv[117]	coref|coref	14-13|14-13[136_117]
12-17	1910-1925	transplantation	abstract[113]|event[115]|event[117]	new[113]|giv[115]|giv[117]	_	_
12-18	1926-1927	,	_	_	_	_
12-19	1928-1931	and	_	_	_	_
12-20	1932-1935	the	abstract[118]	giv[118]	coref	14-8[0_118]
12-21	1936-1940	risk	abstract[118]	giv[118]	_	_
12-22	1941-1943	of	abstract[118]	giv[118]	_	_
12-23	1944-1947	AKI	abstract[118]|abstract	giv[118]|giv	coref	14-11
12-24	1948-1951	may	_	_	_	_
12-25	1952-1960	increase	_	_	_	_
12-26	1961-1965	when	_	_	_	_
12-27	1966-1974	patients	person[120]	giv[120]	coref	13-19[0_120]
12-28	1975-1979	with	person[120]	giv[120]	_	_
12-29	1980-1985	ABO-i	person[120]|abstract|abstract[122]	giv[120]|giv|giv[122]	coref|coref	18-11|18-12[0_122]
12-30	1986-1988	LT	person[120]|abstract[122]	giv[120]|giv[122]	_	_
12-31	1989-1996	receive	_	_	_	_
12-32	1997-2011	intraoperative	abstract[124]	giv[124]	_	_
12-33	2012-2015	FFP	substance|abstract[124]	giv|giv[124]	coref	13-13
12-34	2016-2028	transfusions	abstract[124]	giv[124]	_	_
12-35	2029-2030	.	_	_	_	_

#Text=Furthermore , an inflammatory , allergic , and immunologic reaction triggered by FFP transfusion may be exacerbated when patients receive additional intraoperative FFP .
13-1	2031-2042	Furthermore	_	_	_	_
13-2	2043-2044	,	_	_	_	_
13-3	2045-2047	an	event[125]	new[125]	_	_
13-4	2048-2060	inflammatory	event[125]	new[125]	_	_
13-5	2061-2062	,	event[125]	new[125]	_	_
13-6	2063-2071	allergic	event[125]	new[125]	_	_
13-7	2072-2073	,	event[125]	new[125]	_	_
13-8	2074-2077	and	event[125]	new[125]	_	_
13-9	2078-2089	immunologic	event[125]	new[125]	_	_
13-10	2090-2098	reaction	event[125]	new[125]	_	_
13-11	2099-2108	triggered	event[125]	new[125]	_	_
13-12	2109-2111	by	event[125]	new[125]	_	_
13-13	2112-2115	FFP	event[125]|substance|abstract[127]	new[125]|giv|giv[127]	coref|coref	13-21[129_0]|14-1[131_127]
13-14	2116-2127	transfusion	event[125]|abstract[127]	new[125]|giv[127]	_	_
13-15	2128-2131	may	_	_	_	_
13-16	2132-2134	be	_	_	_	_
13-17	2135-2146	exacerbated	_	_	_	_
13-18	2147-2151	when	_	_	_	_
13-19	2152-2160	patients	person	giv	coref	18-8[163_0]
13-20	2161-2168	receive	_	_	_	_
13-21	2169-2179	additional	substance[129]	giv[129]	coref	17-14[0_129]
13-22	2180-2194	intraoperative	substance[129]	giv[129]	_	_
13-23	2195-2198	FFP	substance[129]	giv[129]	_	_
13-24	2199-2200	.	_	_	_	_

#Text=Red cell transfusion is also a well-known risk factor of AKI after liver transplantation .
14-1	2201-2204	Red	place[130]|abstract[131]	new[130]|giv[131]	coref|coref	14-6[133_131]|21-4[183_130]
14-2	2205-2209	cell	place[130]|abstract[131]	new[130]|giv[131]	_	_
14-3	2210-2221	transfusion	abstract[131]	giv[131]	_	_
14-4	2222-2224	is	_	_	_	_
14-5	2225-2229	also	_	_	_	_
14-6	2230-2231	a	abstract[133]	giv[133]	coref	15-5[139_133]
14-7	2232-2242	well-known	abstract[133]	giv[133]	_	_
14-8	2243-2247	risk	abstract|abstract[133]	giv|giv[133]	_	_
14-9	2248-2254	factor	abstract[133]	giv[133]	_	_
14-10	2255-2257	of	abstract[133]	giv[133]	_	_
14-11	2258-2261	AKI	abstract[133]|abstract	giv[133]|giv	coref	15-22
14-12	2262-2267	after	abstract[133]	giv[133]	_	_
14-13	2268-2273	liver	abstract[133]|object|event[136]	giv[133]|giv|giv[136]	coref|coref	24-19|24-19[213_136]
14-14	2274-2289	transplantation	abstract[133]|event[136]	giv[133]|giv[136]	_	_
14-15	2290-2291	.	_	_	_	_

#Text=The negative effect of pRBC transfusion is multifaceted and includes a systemic inflammatory response , which contributes to the development of AKI after surgery .
15-1	2292-2295	The	abstract[137]	new[137]	_	_
15-2	2296-2304	negative	abstract[137]	new[137]	_	_
15-3	2305-2311	effect	abstract[137]	new[137]	_	_
15-4	2312-2314	of	abstract[137]	new[137]	_	_
15-5	2315-2319	pRBC	abstract[137]|abstract|abstract[139]	new[137]|giv|giv[139]	coref|coref	16-5[0_139]|17-12
15-6	2320-2331	transfusion	abstract[137]|abstract[139]	new[137]|giv[139]	_	_
15-7	2332-2334	is	_	_	_	_
15-8	2335-2347	multifaceted	_	_	_	_
15-9	2348-2351	and	_	_	_	_
15-10	2352-2360	includes	_	_	_	_
15-11	2361-2362	a	abstract[140]	giv[140]	coref	17-6[0_140]
15-12	2363-2371	systemic	abstract[140]	giv[140]	_	_
15-13	2372-2384	inflammatory	abstract[140]	giv[140]	_	_
15-14	2385-2393	response	abstract[140]	giv[140]	_	_
15-15	2394-2395	,	abstract[140]	giv[140]	_	_
15-16	2396-2401	which	abstract[140]	giv[140]	_	_
15-17	2402-2413	contributes	abstract[140]	giv[140]	_	_
15-18	2414-2416	to	abstract[140]	giv[140]	_	_
15-19	2417-2420	the	abstract[140]|event[141]	giv[140]|new[141]	_	_
15-20	2421-2432	development	abstract[140]|event[141]	giv[140]|new[141]	_	_
15-21	2433-2435	of	abstract[140]|event[141]	giv[140]|new[141]	_	_
15-22	2436-2439	AKI	abstract[140]|event[141]|abstract	giv[140]|new[141]|giv	coref	17-20
15-23	2440-2445	after	abstract[140]	giv[140]	_	_
15-24	2446-2453	surgery	abstract[140]|event	giv[140]|giv	coref	26-5
15-25	2454-2455	.	_	_	_	_

#Text=A large amount of transfusion reflects excessive surgical bleeding , which leads to renal hypoperfusion and ischemia , resulting in poor oxygen delivery .
16-1	2456-2457	A	substance[144]	new[144]	_	_
16-2	2458-2463	large	substance[144]	new[144]	_	_
16-3	2464-2470	amount	substance[144]	new[144]	_	_
16-4	2471-2473	of	substance[144]	new[144]	_	_
16-5	2474-2485	transfusion	substance[144]|abstract	new[144]|giv	coref	17-12[157_0]
16-6	2486-2494	reflects	_	_	_	_
16-7	2495-2504	excessive	event[146]	new[146]	coref	28-18[241_146]
16-8	2505-2513	surgical	event[146]	new[146]	_	_
16-9	2514-2522	bleeding	event[146]	new[146]	_	_
16-10	2523-2524	,	event[146]	new[146]	_	_
16-11	2525-2530	which	event[146]	new[146]	_	_
16-12	2531-2536	leads	event[146]	new[146]	_	_
16-13	2537-2539	to	event[146]	new[146]	_	_
16-14	2540-2545	renal	event[146]|event[147]	new[146]|new[147]	_	_
16-15	2546-2559	hypoperfusion	event[146]|event[147]	new[146]|new[147]	_	_
16-16	2560-2563	and	event[146]	new[146]	_	_
16-17	2564-2572	ischemia	event[146]|abstract	new[146]|new	_	_
16-18	2573-2574	,	_	_	_	_
16-19	2575-2584	resulting	_	_	_	_
16-20	2585-2587	in	_	_	_	_
16-21	2588-2592	poor	event[150]	giv[150]	_	_
16-22	2593-2599	oxygen	substance|event[150]	giv|giv[150]	coref	25-18
16-23	2600-2608	delivery	event[150]	giv[150]	_	_
16-24	2609-2610	.	_	_	_	_

#Text=There was a dose – response relationship between the amount of pRBC and FFP transfusion and the risk of AKI in our study .
17-1	2611-2616	There	_	_	_	_
17-2	2617-2620	was	_	_	_	_
17-3	2621-2622	a	abstract[153]	new[153]	_	_
17-4	2623-2627	dose	abstract|abstract[153]	new|new[153]	coref	27-7[230_0]
17-5	2628-2629	–	abstract[153]	new[153]	_	_
17-6	2630-2638	response	abstract|abstract[153]	giv|new[153]	_	_
17-7	2639-2651	relationship	abstract[153]	new[153]	_	_
17-8	2652-2659	between	abstract[153]	new[153]	_	_
17-9	2660-2663	the	abstract[153]|abstract[154]	new[153]|new[154]	coref	23-3[197_154]
17-10	2664-2670	amount	abstract[153]|abstract[154]	new[153]|new[154]	_	_
17-11	2671-2673	of	abstract[153]|abstract[154]	new[153]|new[154]	_	_
17-12	2674-2678	pRBC	abstract[153]|abstract[154]|abstract|abstract[157]	new[153]|new[154]|giv|giv[157]	coref|coref	18-21|18-21[168_157]
17-13	2679-2682	and	abstract[153]|abstract[154]|abstract[157]	new[153]|new[154]|giv[157]	_	_
17-14	2683-2686	FFP	abstract[153]|abstract[154]|substance|abstract[157]	new[153]|new[154]|giv|giv[157]	coref	21-11
17-15	2687-2698	transfusion	abstract[153]|abstract[154]|abstract[157]	new[153]|new[154]|giv[157]	_	_
17-16	2699-2702	and	_	_	_	_
17-17	2703-2706	the	abstract[158]	new[158]	coref	31-2[0_158]
17-18	2707-2711	risk	abstract[158]	new[158]	_	_
17-19	2712-2714	of	abstract[158]	new[158]	_	_
17-20	2715-2718	AKI	abstract[158]|abstract	new[158]|giv	coref	27-28[236_0]
17-21	2719-2721	in	abstract[158]	new[158]	_	_
17-22	2722-2725	our	abstract[158]|person|abstract[161]	new[158]|giv|giv[161]	ana|ana	18-3[0_161]|20-2
17-23	2726-2731	study	abstract[158]|abstract[161]	new[158]|giv[161]	_	_
17-24	2732-2733	.	_	_	_	_

#Text=However , it is not clear why the patients undergoing ABO-i LT were more susceptible to the deleterious effects of pRBC transfusion .
18-1	2734-2741	However	_	_	_	_
18-2	2742-2743	,	_	_	_	_
18-3	2744-2746	it	abstract	giv	coref	29-6[248_0]
18-4	2747-2749	is	_	_	_	_
18-5	2750-2753	not	_	_	_	_
18-6	2754-2759	clear	_	_	_	_
18-7	2760-2763	why	_	_	_	_
18-8	2764-2767	the	person[163]	giv[163]	_	_
18-9	2768-2776	patients	person[163]	giv[163]	_	_
18-10	2777-2787	undergoing	person[163]	giv[163]	_	_
18-11	2788-2793	ABO-i	person[163]|abstract	giv[163]|giv	coref	23-7
18-12	2794-2796	LT	person[163]|abstract	giv[163]|giv	coref	23-7[199_0]
18-13	2797-2801	were	_	_	_	_
18-14	2802-2806	more	_	_	_	_
18-15	2807-2818	susceptible	_	_	_	_
18-16	2819-2821	to	_	_	_	_
18-17	2822-2825	the	abstract[166]	new[166]	_	_
18-18	2826-2837	deleterious	abstract[166]	new[166]	_	_
18-19	2838-2845	effects	abstract[166]	new[166]	_	_
18-20	2846-2848	of	abstract[166]	new[166]	_	_
18-21	2849-2853	pRBC	abstract[166]|abstract|abstract[168]	new[166]|giv|giv[168]	coref|coref	19-9|19-9[172_168]
18-22	2854-2865	transfusion	abstract[166]|abstract[168]	new[166]|giv[168]	_	_
18-23	2866-2867	.	_	_	_	_

#Text=Possible mechanisms include that the adverse effect of pRBC transfusion may be aggravated by a high isoagglutinin titer .
19-1	2868-2876	Possible	abstract[169]	new[169]	_	_
19-2	2877-2887	mechanisms	abstract[169]	new[169]	_	_
19-3	2888-2895	include	_	_	_	_
19-4	2896-2900	that	_	_	_	_
19-5	2901-2904	the	abstract[170]	new[170]	_	_
19-6	2905-2912	adverse	abstract[170]	new[170]	_	_
19-7	2913-2919	effect	abstract[170]	new[170]	_	_
19-8	2920-2922	of	abstract[170]	new[170]	_	_
19-9	2923-2927	pRBC	abstract[170]|abstract|abstract[172]	new[170]|giv|giv[172]	coref|coref	21-4[184_172]|22-15
19-10	2928-2939	transfusion	abstract[170]|abstract[172]	new[170]|giv[172]	_	_
19-11	2940-2943	may	_	_	_	_
19-12	2944-2946	be	_	_	_	_
19-13	2947-2957	aggravated	_	_	_	_
19-14	2958-2960	by	_	_	_	_
19-15	2961-2962	a	object[174]	giv[174]	coref	20-17[180_174]
19-16	2963-2967	high	object[174]	giv[174]	_	_
19-17	2968-2981	isoagglutinin	substance|object[174]	giv|giv[174]	coref	20-18
19-18	2982-2987	titer	object[174]	giv[174]	_	_
19-19	2988-2989	.	_	_	_	_

#Text=Although we accounted for confounding factors through propensity-score-matching and multivariable analysis , we could not adjust the isoagglutinin titer due to a lack of data .
20-1	2990-2998	Although	_	_	_	_
20-2	2999-3001	we	person	giv	ana	20-13
20-3	3002-3011	accounted	_	_	_	_
20-4	3012-3015	for	_	_	_	_
20-5	3016-3027	confounding	abstract[176]	giv[176]	_	_
20-6	3028-3035	factors	abstract[176]	giv[176]	_	_
20-7	3036-3043	through	_	_	_	_
20-8	3044-3069	propensity-score-matching	abstract[177]	giv[177]	coref	34-13[274_177]
20-9	3070-3073	and	abstract[177]	giv[177]	_	_
20-10	3074-3087	multivariable	abstract[177]	giv[177]	_	_
20-11	3088-3096	analysis	abstract[177]	giv[177]	_	_
20-12	3097-3098	,	_	_	_	_
20-13	3099-3101	we	person	giv	ana	23-10
20-14	3102-3107	could	_	_	_	_
20-15	3108-3111	not	_	_	_	_
20-16	3112-3118	adjust	_	_	_	_
20-17	3119-3122	the	object[180]	giv[180]	_	_
20-18	3123-3136	isoagglutinin	substance|object[180]	giv|giv[180]	_	_
20-19	3137-3142	titer	object[180]	giv[180]	_	_
20-20	3143-3146	due	_	_	_	_
20-21	3147-3149	to	_	_	_	_
20-22	3150-3151	a	abstract[181]	new[181]	_	_
20-23	3152-3156	lack	abstract[181]	new[181]	_	_
20-24	3157-3159	of	abstract[181]	new[181]	_	_
20-25	3160-3164	data	abstract[181]|abstract	new[181]|new	_	_
20-26	3165-3166	.	_	_	_	_

#Text=In addition , red cell transfusion is closely related to FFP transfusion .
21-1	3167-3169	In	_	_	_	_
21-2	3170-3178	addition	_	_	_	_
21-3	3179-3180	,	_	_	_	_
21-4	3181-3184	red	place[183]|abstract[184]	giv[183]|giv[184]	coref|coref	21-11[186_184]|26-1[222_183]
21-5	3185-3189	cell	place[183]|abstract[184]	giv[183]|giv[184]	_	_
21-6	3190-3201	transfusion	abstract[184]	giv[184]	_	_
21-7	3202-3204	is	_	_	_	_
21-8	3205-3212	closely	_	_	_	_
21-9	3213-3220	related	_	_	_	_
21-10	3221-3223	to	_	_	_	_
21-11	3224-3227	FFP	substance|abstract[186]	giv|giv[186]	coref|coref	22-2|22-1[188_186]
21-12	3228-3239	transfusion	abstract[186]	giv[186]	_	_
21-13	3240-3241	.	_	_	_	_

#Text=Cumulative FFP transfusion after preoperative plasma exchange could be the leading cause , and pRBC transfusion could be a simple association .
22-1	3242-3252	Cumulative	abstract[188]	giv[188]	coref	22-10[191_188]
22-2	3253-3256	FFP	substance|abstract[188]	giv|giv[188]	_	_
22-3	3257-3268	transfusion	abstract[188]	giv[188]	_	_
22-4	3269-3274	after	abstract[188]	giv[188]	_	_
22-5	3275-3287	preoperative	abstract[188]|event[190]	giv[188]|giv[190]	_	_
22-6	3288-3294	plasma	abstract[188]|substance|event[190]	giv[188]|giv|giv[190]	_	_
22-7	3295-3303	exchange	abstract[188]|event[190]	giv[188]|giv[190]	_	_
22-8	3304-3309	could	_	_	_	_
22-9	3310-3312	be	_	_	_	_
22-10	3313-3316	the	abstract[191]|abstract[192]	giv[191]|giv[192]	coref|coref	22-10[192_191]|22-15[194_192]
22-11	3317-3324	leading	abstract[191]|abstract[192]	giv[191]|giv[192]	_	_
22-12	3325-3330	cause	abstract[191]|abstract[192]	giv[191]|giv[192]	_	_
22-13	3331-3332	,	abstract[192]	giv[192]	_	_
22-14	3333-3336	and	abstract[192]	giv[192]	_	_
22-15	3337-3341	pRBC	abstract[192]|abstract|abstract[194]	giv[192]|giv|giv[194]	coref|coref	22-19[195_194]|24-12
22-16	3342-3353	transfusion	abstract[192]|abstract[194]	giv[192]|giv[194]	_	_
22-17	3354-3359	could	abstract[192]	giv[192]	_	_
22-18	3360-3362	be	abstract[192]	giv[192]	_	_
22-19	3363-3364	a	abstract[192]|abstract[195]	giv[192]|giv[195]	coref	23-4[0_195]
22-20	3365-3371	simple	abstract[192]|abstract[195]	giv[192]|giv[195]	_	_
22-21	3372-3383	association	abstract[192]|abstract[195]	giv[192]|giv[195]	_	_
22-22	3384-3385	.	_	_	_	_

#Text=To reduce the transfusion amount in ABO-i LT , we could adopt a restrictive transfusion policy by decreasing the transfusion threshold .
23-1	3386-3388	To	_	_	_	_
23-2	3389-3395	reduce	_	_	_	_
23-3	3396-3399	the	abstract[197]	giv[197]	coref	27-16[233_197]
23-4	3400-3411	transfusion	abstract|abstract[197]	giv|giv[197]	coref	23-15
23-5	3412-3418	amount	abstract[197]	giv[197]	_	_
23-6	3419-3421	in	abstract[197]	giv[197]	_	_
23-7	3422-3427	ABO-i	abstract[197]|abstract|abstract[199]	giv[197]|giv|giv[199]	coref|coref	30-6|30-6[254_199]
23-8	3428-3430	LT	abstract[197]|abstract[199]	giv[197]|giv[199]	_	_
23-9	3431-3432	,	_	_	_	_
23-10	3433-3435	we	person	giv	ana	24-16
23-11	3436-3441	could	_	_	_	_
23-12	3442-3447	adopt	_	_	_	_
23-13	3448-3449	a	abstract[202]	new[202]	_	_
23-14	3450-3461	restrictive	abstract[202]	new[202]	_	_
23-15	3462-3473	transfusion	abstract|abstract[202]	giv|new[202]	coref	23-20
23-16	3474-3480	policy	abstract[202]	new[202]	_	_
23-17	3481-3483	by	_	_	_	_
23-18	3484-3494	decreasing	_	_	_	_
23-19	3495-3498	the	abstract[204]	new[204]	coref	24-11[209_204]
23-20	3499-3510	transfusion	abstract|abstract[204]	giv|new[204]	coref	24-8[206_0]
23-21	3511-3520	threshold	abstract[204]	new[204]	_	_
23-22	3521-3522	.	_	_	_	_

#Text=Although there is no established consensus regarding intraoperative transfusion , the pRBC transfusion threshold in our institution during liver transplantation was around 20 % in hematocrit .
24-1	3523-3531	Although	_	_	_	_
24-2	3532-3537	there	_	_	_	_
24-3	3538-3540	is	_	_	_	_
24-4	3541-3543	no	abstract[205]	new[205]	_	_
24-5	3544-3555	established	abstract[205]	new[205]	_	_
24-6	3556-3565	consensus	abstract[205]	new[205]	_	_
24-7	3566-3575	regarding	abstract[205]	new[205]	_	_
24-8	3576-3590	intraoperative	abstract[205]|abstract[206]	new[205]|giv[206]	coref	24-13[0_206]
24-9	3591-3602	transfusion	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
24-10	3603-3604	,	_	_	_	_
24-11	3605-3608	the	abstract[209]	giv[209]	coref	24-22[214_209]
24-12	3609-3613	pRBC	abstract|abstract[209]	giv|giv[209]	_	_
24-13	3614-3625	transfusion	abstract|abstract[209]	giv|giv[209]	coref	26-1[223_0]
24-14	3626-3635	threshold	abstract[209]	giv[209]	_	_
24-15	3636-3638	in	abstract[209]	giv[209]	_	_
24-16	3639-3642	our	abstract[209]|person|organization[211]	giv[209]|giv|new[211]	ana	29-6
24-17	3643-3654	institution	abstract[209]|organization[211]	giv[209]|new[211]	_	_
24-18	3655-3661	during	abstract[209]	giv[209]	_	_
24-19	3662-3667	liver	abstract[209]|object|event[213]	giv[209]|giv|giv[213]	_	_
24-20	3668-3683	transplantation	abstract[209]|event[213]	giv[209]|giv[213]	_	_
24-21	3684-3687	was	_	_	_	_
24-22	3688-3694	around	abstract[214]	giv[214]	coref	25-1[216_214]
24-23	3695-3697	20	abstract[214]	giv[214]	_	_
24-24	3698-3699	%	abstract[214]	giv[214]	_	_
24-25	3700-3702	in	abstract[214]	giv[214]	_	_
24-26	3703-3713	hematocrit	abstract[214]|abstract	giv[214]|new	coref	26-12[225_0]
24-27	3714-3715	.	_	_	_	_

#Text=This threshold could be lowered further depending on the baseline status of recipients or the mixed venous oxygen concentrations .
25-1	3716-3720	This	abstract[216]	giv[216]	_	_
25-2	3721-3730	threshold	abstract[216]	giv[216]	_	_
25-3	3731-3736	could	_	_	_	_
25-4	3737-3739	be	_	_	_	_
25-5	3740-3747	lowered	_	_	_	_
25-6	3748-3755	further	_	_	_	_
25-7	3756-3765	depending	_	_	_	_
25-8	3766-3768	on	_	_	_	_
25-9	3769-3772	the	abstract[218]	new[218]	_	_
25-10	3773-3781	baseline	abstract|abstract[218]	giv|new[218]	_	_
25-11	3782-3788	status	abstract[218]	new[218]	_	_
25-12	3789-3791	of	abstract[218]	new[218]	_	_
25-13	3792-3802	recipients	abstract[218]|person	new[218]|new	_	_
25-14	3803-3805	or	abstract[218]	new[218]	_	_
25-15	3806-3809	the	abstract[218]|abstract[221]	new[218]|new[221]	_	_
25-16	3810-3815	mixed	abstract[218]|abstract[221]	new[218]|new[221]	_	_
25-17	3816-3822	venous	abstract[218]|abstract[221]	new[218]|new[221]	_	_
25-18	3823-3829	oxygen	abstract[218]|substance|abstract[221]	new[218]|giv|new[221]	_	_
25-19	3830-3844	concentrations	abstract[218]|abstract[221]	new[218]|new[221]	_	_
25-20	3845-3846	.	_	_	_	_

#Text=Red cell transfusion during surgery could possibly be reduced by optimizing baseline hematocrit before surgery through the administration of erythropoietin .
26-1	3847-3850	Red	place[222]|abstract[223]	giv[222]|giv[223]	coref	27-17[0_223]
26-2	3851-3855	cell	place[222]|abstract[223]	giv[222]|giv[223]	_	_
26-3	3856-3867	transfusion	abstract[223]	giv[223]	_	_
26-4	3868-3874	during	abstract[223]	giv[223]	_	_
26-5	3875-3882	surgery	abstract[223]|event	giv[223]|giv	coref	26-15
26-6	3883-3888	could	_	_	_	_
26-7	3889-3897	possibly	_	_	_	_
26-8	3898-3900	be	_	_	_	_
26-9	3901-3908	reduced	_	_	_	_
26-10	3909-3911	by	_	_	_	_
26-11	3912-3922	optimizing	_	_	_	_
26-12	3923-3931	baseline	abstract[225]	giv[225]	_	_
26-13	3932-3942	hematocrit	abstract[225]	giv[225]	_	_
26-14	3943-3949	before	_	_	_	_
26-15	3950-3957	surgery	event	giv	coref	27-20[234_0]
26-16	3958-3965	through	_	_	_	_
26-17	3966-3969	the	event[227]	new[227]	_	_
26-18	3970-3984	administration	event[227]	new[227]	_	_
26-19	3985-3987	of	event[227]	new[227]	_	_
26-20	3988-4002	erythropoietin	event[227]|abstract	new[227]|new	coref	27-13
26-21	4003-4004	.	_	_	_	_

#Text=A previous randomized trial reported that a preoperative single intravenous dose of erythropoietin could reduce the transfusion amount during cardiac surgery , thereby reducing the incidence of postoperative AKI .
27-1	4005-4006	A	abstract[229]	new[229]	_	_
27-2	4007-4015	previous	abstract[229]	new[229]	_	_
27-3	4016-4026	randomized	abstract[229]	new[229]	_	_
27-4	4027-4032	trial	abstract[229]	new[229]	_	_
27-5	4033-4041	reported	_	_	_	_
27-6	4042-4046	that	_	_	_	_
27-7	4047-4048	a	abstract[230]	giv[230]	_	_
27-8	4049-4061	preoperative	abstract[230]	giv[230]	_	_
27-9	4062-4068	single	abstract[230]	giv[230]	_	_
27-10	4069-4080	intravenous	abstract[230]	giv[230]	_	_
27-11	4081-4085	dose	abstract[230]	giv[230]	_	_
27-12	4086-4088	of	abstract[230]	giv[230]	_	_
27-13	4089-4103	erythropoietin	abstract[230]|abstract	giv[230]|giv	_	_
27-14	4104-4109	could	_	_	_	_
27-15	4110-4116	reduce	_	_	_	_
27-16	4117-4120	the	abstract[233]	giv[233]	_	_
27-17	4121-4132	transfusion	abstract|abstract[233]	giv|giv[233]	coref	28-6
27-18	4133-4139	amount	abstract[233]	giv[233]	_	_
27-19	4140-4146	during	_	_	_	_
27-20	4147-4154	cardiac	event[234]	giv[234]	_	_
27-21	4155-4162	surgery	event[234]	giv[234]	_	_
27-22	4163-4164	,	_	_	_	_
27-23	4165-4172	thereby	_	_	_	_
27-24	4173-4181	reducing	_	_	_	_
27-25	4182-4185	the	abstract[235]	new[235]	_	_
27-26	4186-4195	incidence	abstract[235]	new[235]	_	_
27-27	4196-4198	of	abstract[235]	new[235]	_	_
27-28	4199-4212	postoperative	abstract[235]|abstract[236]	new[235]|giv[236]	coref	29-4[0_236]
27-29	4213-4216	AKI	abstract[235]|abstract[236]	new[235]|giv[236]	_	_
27-30	4217-4218	.	_	_	_	_

#Text=In addition , to reduce transfusion requirements , the intraoperative use of vasopressin was reported to reduce surgical bleeding through selective splanchnic vasoconstriction and by reducing portal blood flow .
28-1	4219-4221	In	_	_	_	_
28-2	4222-4230	addition	_	_	_	_
28-3	4231-4232	,	_	_	_	_
28-4	4233-4235	to	_	_	_	_
28-5	4236-4242	reduce	_	_	_	_
28-6	4243-4254	transfusion	abstract|abstract[238]	giv|new[238]	_	_
28-7	4255-4267	requirements	abstract[238]	new[238]	_	_
28-8	4268-4269	,	_	_	_	_
28-9	4270-4273	the	event[239]	new[239]	_	_
28-10	4274-4288	intraoperative	event[239]	new[239]	_	_
28-11	4289-4292	use	event[239]	new[239]	_	_
28-12	4293-4295	of	event[239]	new[239]	_	_
28-13	4296-4307	vasopressin	event[239]|object	new[239]|new	_	_
28-14	4308-4311	was	_	_	_	_
28-15	4312-4320	reported	_	_	_	_
28-16	4321-4323	to	_	_	_	_
28-17	4324-4330	reduce	_	_	_	_
28-18	4331-4339	surgical	event[241]	giv[241]	_	_
28-19	4340-4348	bleeding	event[241]	giv[241]	_	_
28-20	4349-4356	through	_	_	_	_
28-21	4357-4366	selective	event[242]	new[242]	_	_
28-22	4367-4377	splanchnic	event[242]	new[242]	_	_
28-23	4378-4394	vasoconstriction	event[242]	new[242]	_	_
28-24	4395-4398	and	_	_	_	_
28-25	4399-4401	by	_	_	_	_
28-26	4402-4410	reducing	_	_	_	_
28-27	4411-4417	portal	substance[243]|abstract[244]	new[243]|new[244]	_	_
28-28	4418-4423	blood	substance[243]|abstract[244]	new[243]|new[244]	_	_
28-29	4424-4428	flow	abstract[244]	new[244]	_	_
28-30	4429-4430	.	_	_	_	_

#Text=The incidence of AKI in our study was within the range reported in previous literature .
29-1	4431-4434	The	abstract[245]	new[245]	_	_
29-2	4435-4444	incidence	abstract[245]	new[245]	_	_
29-3	4445-4447	of	abstract[245]	new[245]	_	_
29-4	4448-4451	AKI	abstract[245]|abstract	new[245]|giv	coref	30-4
29-5	4452-4454	in	abstract[245]	new[245]	_	_
29-6	4455-4458	our	abstract[245]|person|abstract[248]	new[245]|giv|giv[248]	coref|ana	30-12[255_248]|34-13
29-7	4459-4464	study	abstract[245]|abstract[248]	new[245]|giv[248]	_	_
29-8	4465-4468	was	_	_	_	_
29-9	4469-4475	within	_	_	_	_
29-10	4476-4479	the	abstract[249]	new[249]	_	_
29-11	4480-4485	range	abstract[249]	new[249]	_	_
29-12	4486-4494	reported	abstract[249]	new[249]	_	_
29-13	4495-4497	in	abstract[249]	new[249]	_	_
29-14	4498-4506	previous	abstract[249]|abstract[250]	new[249]|new[250]	coref	31-16[262_250]
29-15	4507-4517	literature	abstract[249]|abstract[250]	new[249]|new[250]	_	_
29-16	4518-4519	.	_	_	_	_

#Text=The incidence of AKI in ABO-i LT was also similar to a previous study .
30-1	4520-4523	The	abstract[251]	new[251]	_	_
30-2	4524-4533	incidence	abstract[251]	new[251]	_	_
30-3	4534-4536	of	abstract[251]	new[251]	_	_
30-4	4537-4540	AKI	abstract[251]|abstract	new[251]|giv	coref	31-5
30-5	4541-4543	in	abstract[251]	new[251]	_	_
30-6	4544-4549	ABO-i	abstract[251]|abstract|abstract[254]	new[251]|giv|giv[254]	coref|coref	31-8|31-8[260_254]
30-7	4550-4552	LT	abstract[251]|abstract[254]	new[251]|giv[254]	_	_
30-8	4553-4556	was	_	_	_	_
30-9	4557-4561	also	_	_	_	_
30-10	4562-4569	similar	_	_	_	_
30-11	4570-4572	to	_	_	_	_
30-12	4573-4574	a	abstract[255]	giv[255]	_	_
30-13	4575-4583	previous	abstract[255]	giv[255]	_	_
30-14	4584-4589	study	abstract[255]	giv[255]	_	_
30-15	4590-4591	.	_	_	_	_

#Text=The risk factors of AKI other than ABO-i LT were mostly consistent with those of the previous literature .
31-1	4592-4595	The	abstract[257]	new[257]	_	_
31-2	4596-4600	risk	abstract|abstract[257]	giv|new[257]	_	_
31-3	4601-4608	factors	abstract[257]	new[257]	_	_
31-4	4609-4611	of	abstract[257]	new[257]	_	_
31-5	4612-4615	AKI	abstract[257]|abstract	new[257]|giv	coref	32-9[265_0]
31-6	4616-4621	other	abstract[257]	new[257]	_	_
31-7	4622-4626	than	_	_	_	_
31-8	4627-4632	ABO-i	abstract|abstract[260]	giv|giv[260]	ana	31-14[261_260]
31-9	4633-4635	LT	abstract[260]	giv[260]	_	_
31-10	4636-4640	were	_	_	_	_
31-11	4641-4647	mostly	_	_	_	_
31-12	4648-4658	consistent	_	_	_	_
31-13	4659-4663	with	_	_	_	_
31-14	4664-4669	those	abstract[261]	giv[261]	_	_
31-15	4670-4672	of	abstract[261]	giv[261]	_	_
31-16	4673-4676	the	abstract[261]|abstract[262]	giv[261]|giv[262]	_	_
31-17	4677-4685	previous	abstract[261]|abstract[262]	giv[261]|giv[262]	_	_
31-18	4686-4696	literature	abstract[261]|abstract[262]	giv[261]|giv[262]	_	_
31-19	4697-4698	.	_	_	_	_

#Text=The preoperative hemoglobin level was independently associated with post-transplant AKI .
32-1	4699-4702	The	abstract[264]	new[264]	_	_
32-2	4703-4715	preoperative	abstract[264]	new[264]	_	_
32-3	4716-4726	hemoglobin	abstract|abstract[264]	new|new[264]	_	_
32-4	4727-4732	level	abstract[264]	new[264]	_	_
32-5	4733-4736	was	_	_	_	_
32-6	4737-4750	independently	_	_	_	_
32-7	4751-4761	associated	_	_	_	_
32-8	4762-4766	with	_	_	_	_
32-9	4767-4782	post-transplant	abstract[265]	giv[265]	coref	33-13[0_265]
32-10	4783-4786	AKI	abstract[265]	giv[265]	_	_
32-11	4787-4788	.	_	_	_	_

#Text=The MELD score has been consistently reported to be a predictor of AKI .
33-1	4789-4792	The	abstract[267]	new[267]	_	_
33-2	4793-4797	MELD	abstract|abstract[267]	new|new[267]	_	_
33-3	4798-4803	score	abstract[267]	new[267]	_	_
33-4	4804-4807	has	_	_	_	_
33-5	4808-4812	been	_	_	_	_
33-6	4813-4825	consistently	_	_	_	_
33-7	4826-4834	reported	_	_	_	_
33-8	4835-4837	to	_	_	_	_
33-9	4838-4840	be	_	_	_	_
33-10	4841-4842	a	abstract[268]	new[268]	_	_
33-11	4843-4852	predictor	abstract[268]	new[268]	_	_
33-12	4853-4855	of	abstract[268]	new[268]	_	_
33-13	4856-4859	AKI	abstract[268]|abstract	new[268]|giv	coref	34-11
33-14	4860-4861	.	_	_	_	_

#Text=Ischemic time was not identified as an independent predictor of AKI in our analysis , which could have been due to the relatively short ischemic time of LDLT .
34-1	4862-4870	Ischemic	time[270]	new[270]	_	_
34-2	4871-4875	time	time[270]	new[270]	_	_
34-3	4876-4879	was	_	_	_	_
34-4	4880-4883	not	_	_	_	_
34-5	4884-4894	identified	_	_	_	_
34-6	4895-4897	as	_	_	_	_
34-7	4898-4900	an	abstract[271]	new[271]	_	_
34-8	4901-4912	independent	abstract[271]	new[271]	_	_
34-9	4913-4922	predictor	abstract[271]	new[271]	_	_
34-10	4923-4925	of	abstract[271]	new[271]	_	_
34-11	4926-4929	AKI	abstract[271]|abstract	new[271]|giv	_	_
34-12	4930-4932	in	_	_	_	_
34-13	4933-4936	our	person|abstract[274]	giv|giv[274]	_	_
34-14	4937-4945	analysis	abstract[274]	giv[274]	_	_
34-15	4946-4947	,	abstract[274]	giv[274]	_	_
34-16	4948-4953	which	abstract[274]	giv[274]	_	_
34-17	4954-4959	could	abstract[274]	giv[274]	_	_
34-18	4960-4964	have	abstract[274]	giv[274]	_	_
34-19	4965-4969	been	abstract[274]	giv[274]	_	_
34-20	4970-4973	due	abstract[274]	giv[274]	_	_
34-21	4974-4976	to	abstract[274]	giv[274]	_	_
34-22	4977-4980	the	abstract[274]|time[275]	giv[274]|new[275]	_	_
34-23	4981-4991	relatively	abstract[274]|time[275]	giv[274]|new[275]	_	_
34-24	4992-4997	short	abstract[274]|time[275]	giv[274]|new[275]	_	_
34-25	4998-5006	ischemic	abstract[274]|time[275]	giv[274]|new[275]	_	_
34-26	5007-5011	time	abstract[274]|time[275]	giv[274]|new[275]	_	_
34-27	5012-5014	of	abstract[274]|time[275]	giv[274]|new[275]	_	_
34-28	5015-5019	LDLT	abstract[274]|time[275]|abstract	giv[274]|new[275]|new	_	_
34-29	5020-5021	.	_	_	_	_
